A potential game changer in the treatment of retinal disease, the novel dual-target drug shows encouraging results.

TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is deepening its collaboration with ...

Ingelheim, Germany, May 6, 2025 - Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential ...

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

A pioneering clinical study found that pairing vagus nerve stimulation (VNS) with traditional therapy eliminated PTSD ...

U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb ...

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue, while reporting ...

In a recent clinical study, patients with treatment-resistant post-traumatic stress disorder were symptom-free up to six months after completing traditional therapy paired with vagus nerve stimulation ...

Net Loss: The Company reported a net loss attributable to common stockholders of $29.3 million for the three months ended March 31, 2025, which included $3.2 million of stock-based compensation, ...

An government research lab that had been used to conduct “cruel” and deadly drug experiments on beagles has been shut down, ...

Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...

Recent study investigates the potential of preoperative airway ultrasonography (USG) measurements to predict difficult ...